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Abstract 
Background and objectives: Several studies demonstrate that cerebral preconditioning is a 
protective mechanism against a stressful situation. Preconditioning determinants are described, 
as well as the neuroprotection provided by anesthetic and non-anesthetics agents.
Content: Review based on the main articles addressing the pathophysiology of ischemia-reperfusion 
and neuronal injury and pharmacological and non-pharmacological factors (inﬂ ammation, 
glycemia, and temperature) related to the change in response to ischemia-reperfusion, in addition 
to neuroprotection induced by anesthetic use.
Conclusions: The brain has the ability to protect itself against ischemia when stimulated. The 
elucidation of this mechanism enables the application of preconditioning inducing substances 
(some anesthetics), other drugs, and non-pharmacological measures, such as hypothermia, aimed 
at inducing tolerance to ischemic lesions.
© 2013 Sociedade Brasileira de Anestesiologia.Published by Elsevier Editora Ltda. 
Anesthetics, Cerebral Protection and Preconditioning
Rogean Rodrigues Nunes* 1, Gastão Fernandes Duval Neto 2, 
Júlio César Garcia de Alencar 3, Suyane Benevides Franco 3, 
Nayanna Quezado de Andrade 3, Danielle Maia Holanda Dumaresq 4 
Sara Lúcia Cavalcante 5
1. TSA; MSc and PhD in Anesthetics; Postgraduate in Cardiology, Universidade Federal do Ceará (UFC); Jointly 
Responsible for the Center for Teaching and Training (CET) of Hospital Geral de Fortaleza (HGF); Medicine Professor of 
Fachristus; Postgraduate in Clinical Engineering, Universidade de Fortaleza (Unifor); Vice-Chair of the Research Ethics 
Committee, Hospital São Carlos, Fortaleza, Ceará 
2. TSA; Full Professor; PhD; Department of General Surgery, Universidade Federal de Pelotas (UFPel) 
3. Medical Student, UFC 
4. TSA; MSc, UFC; Responsible for CET-IJF; Chairman of the Pediatric Anesthesia Committee, Sociedade 
Brasileira de Anestesiologia (SBA) – 2011; Medicine Professor of Fachristus, Fortaleza, Ceará
5. PhD; Professor, Faculdade de Medicina, UFC; Corresponsible for the CET of the HGF from Hospital São Carlos, Fortaleza, 
Ceara, Brazil.
Received from Hospital Sao Carlos, Fortaleza, Ceara, Brazil.
Submitted on October 14, 2011. Approved on June 16, 2012.
Keywords: 
Ischemic 
Preconditioning; 
Ischemia; Central 
Nervous System; 
Anesthetics; 
Hypothermia.
REVIEW ARTICLE
ISSN © 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
* Corresponding author: Av. Comendador Francisco Ângelo, 1185 
Lourdes, Fortaleza, Ceará, Brazil 
E-mail: rogean@fortalnet.com.br
Introduction
The ability to respond to stressful situations is a fundamental 
property of all living organisms 1. Surviving a sublethal insult 
may result in a protective state to a subsequent lethal in-
sult. This phenomenon is seen in various organs, particularly 
brain and heart, and called cerebral preconditioning (CP) 
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dismutase, and glutathione peroxidase are enzyme systems 
involved in neutralizing these radicals. Ascorbic acid (vitamin 
C) and tocopherol (vitamin E) are also responsible for some 
protection against these radicals 15,16.
Gamma-Aminobutyric acid (GABA) and glycine are the 
nervous system main inhibitory neurotransmitters control-
ling the opening of chloride or potassium channels. GABA 
receptors are frequent targets of anesthetics that, besides 
reducing neuronal excitation, induce neuroprotection by 
reducing the excitotoxicity.
The major neuronal excitatory amino acid is glutamate, 
a metabotropic and ionotropic receptor agonist (NMDA and 
non-NMDA). Activation of ionotropic receptors results in the 
opening of an ion channel in the postsynaptic membrane. 
NMDA ionotropic glutamate receptors open calcium channels. 
Non-NMDA receptors open channels that are permeable to 
sodium and potassium. Metabotropic receptors are linked to 
G protein, a second messenger that has a guanidine nucle-
oside. The binding of glutamate to its metabotropic receptors 
results in the activation of phospholipases A2 and C.
During reperfusion, synergistic action of reactive oxy-
gen species and glutamate leads to increased metabolism 
of arachidonic acid into leukotrienes via lipoxygenase, 
thromboxanes, prostacyclins, and prostaglandins via the 
cyclooxygenase pathway 17-18. These molecules increased con-
centration seems to be involved in cytotoxic edema and the 
damage of organelles and plasma membranes 19. The action of 
glutamate results in increased concentration of intracellular 
calcium. Excess calcium ion has a harmful effect due to the 
activation of proteases and phospholipases.
Despite the great importance given to calcium regard-
ing the pathophysiology of ischemia/reperfusion, several 
studies evaluating the effect of substances that decrease 
calcium entry into the cell failed to establish the efﬁ cacy 
of this approach in neuroprotection 10. Voltage-independent 
calcium channels are divided into four subtypes, character-
ized by threshold activation, conductance, and location 20. 
The N-type and L-type seem to be involved in the patho-
physiology of ischemia/reperfusion. N-type channels are 
related to the release of neurotransmitters in the synaptic 
cleft and L-type channels are related to changes in neuron 
metabolism. Substances derived from dihydropyridine and 
phenylalkylamine act by blocking the L-type calcium chan-
nel. Experimental models of focal ischemia associate its 
use with a decrease in mortality and neurological function 
improvement 21.
Αlpha-2 agonists in vivo have been shown to attenuate 
neurological injuries after ganglionic blockade with hexam-
ethonium in rat models of incomplete cerebral ischemia 22. 
The development of an anesthetic with an adjunct α-2 agonist 
action must include its use as a neuroprotective agent 23.
Nitric oxide (NO) is a gas that acts as a neuromodulator 
in glutaminergic synapses by oxidizing sulfhydryl residues 
of NMDA receptors, inactivating them 24. NO can also react 
with oxygen radicals and generate reactive nitrogen species, 
which react with the proton (H+) and produce the potent 
hydroxyl radical 25.
Lipopolysaccharide (LPS) is a cell wall component of 
Gram-negative bacteria. A small dose of LPS can result in 
brain ischemic tolerance (BIT). This has been proven by a 
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or ischemic tolerance (IT) 2. The ﬁ rst in vivo evidences of 
CP dates back to the 1960s 3,4. Nearly three decades have 
passed with no interest from researchers on this mechanism, 
until Kitagawa et al. 5 started the era of ischemic tolerance 
research.
The main pathophysiological aspects involved in cerebral 
ischemia/reperfusion are caused by the excitotoxic actions of 
glutamate, ATP consumption, changes in ionic homeostasis, 
and formation of free radicals. Anesthetics, hypothermia, 
sodium channel blockers, and ascorbic acid are among the 
many substances that provide protection to the nervous 
system acting on these points 6,7.
It occurs in two distinct time frames: early and late toler-
ance. Early tolerance main mechanism is the adaptation of 
membrane receptors, which can be achieved within minutes, 
but decreases rapidly within hours. Late tolerance, through 
gene activation with subsequent synthesis of new proteins, 
is achieved within hours and can last for several days 2.
In humans, transient ischemic attacks (TIAs) may be a 
clinical sign of preconditioning. Mimicking the mechanisms of 
this process of endogenous protection is therefore a potential 
strategy for stroke prevention 2.
The relevance of brain protection in clinical practice can 
be found during cardiopulmonary resuscitation 8 and before 
surgical procedures that intentionally require maintaining 
periods of cerebral ischemia/hypoperfusion. The anesthesi-
ologist is then faced with the possibility of actively preparing 
the nervous system for the ischemia-reperfusion events and 
thereby preventing possible related injuries.
Pathophysiology of ischemia-reperfusion 
and neuronal injury
The brain performs its functions through complex signaling 
pathways between nerve cells. Information transmission 
between neurons depends on tissue integrity 9. The cen-
tral nervous system consumes high levels of oxygen and 
glucose, which are metabolized by oxidative phosphoryla-
tion. The normal cerebral blood ﬂ ow in humans ﬂ uctu-
ates around 50 mL.100g-1.min-1; when this value reaches 
about 10 mL.100g-1min-1, it is estimated that a potential 
neuronal loss occurs, which leads to neurological function 
deterioration.
Complete cerebral ischemia or decreased cerebral blood 
ﬂ ow, followed by reperfusion, triggers deep changes in neuro-
nal metabolism. During ischemia, there are: increased cell ca-
tabolism; decreased amount of ATP available; Na+/K+-ATPase 
dysfunction; intracellular sodium accumulation; changes in 
membrane potential; cellular edema; and increased activity 
of excitatory neurotransmitters, such as glutamate 10. The 
anaerobic metabolism of glucose produces lactate and con-
sequent increase in H+ concentration inside the cell 11.
With cerebral reperfusion, there is initially a supply of 
oxygen and glucose greater than the cell capacity to use it 12. 
Hyperglycemia results in increased concentration of lactic 
acid, which follows the initial phase of ischemia and exac-
erbates post-ischemic injuries. Electrochemical reduction 
of oxygen molecules forms reactive oxygen species leading 
to oxidative stress 13,14. Hydroxyl radical (OH-), the most 
potent reactive oxygen species, acts on the breakdown of 
fatty acid molecules of the membrane. Catalase, superoxide 
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number of experiments, which included both transient and 
permanent focal ischemia models. However, high doses of 
LPS had no effect on CP 26.
Consequences of cerebral ischemia/reperfusion may be 
limited to the action on membrane lipids of cellular proteins 
and thus be quickly reversed. When changes are of sufﬁ cient 
magnitude to impair RNA transcription or alter the DNA 
itself, there will be cellular death, which is an irreversible 
phenomenon 10.
In cerebral infarction, necrosis occurs in the central area. 
Peripheral changes are not as severe as central changes; neu-
rons die more slowly and mainly by apoptosis 27. This process 
involves the mitochondrial cytochrome-c, caspase activation, 
and other pro-apoptotic factors. Cytokines, such as IL-1, 
contribute to the occurrence of this neurodegeneration.
Therapies with potential to act on various neuroprotec-
tive inducers are more effective than mono-focal therapies. 
For example, MK-801 (NMDA antagonist) is an excitotoxicity 
suppressor of cell death, but seems to exacerbate apoptotic 
injury 24.
Determinants of ischemic tolerance
Several animal models experiments of global and focal 
ischemia conﬁ rmed that the ischemic tolerance concept, 
introduced two decades ago and initially based on myocar-
dium observations, may be extended to cerebral ischemic 
injury 28-30. Therefore, it is understood that brief ischemic 
episodes protect the brain against subsequent more severe 
ischemia.
Besides sublethal ischemia, other conditions, such as 
hyperthermia 31, hypothermia 32, hypoglycemia 33, and phar-
macological agents (e.g., antibiotics, erythropoietin, ace-
tylsalicylic acid, and volatile anesthetics) induce ischemic 
tolerance 34-37.
The initial phase of ischemic tolerance (up to 30 minutes 
after a sublethal insult) is likely due to metabolic transmem-
brane ﬂ ow events. The delayed phase of tolerance (after 24 
hours) involves genetic induction and protein synthesis 38,39. 
Molecules, such as adenosine, hypoxia inducing factor-1α, 
TNF-α, reactive oxygen species, NO, and other events involv-
ing NMDA receptor activation and intracellular calcium inﬂ ux 
have been implicated in tolerance to ischemia.
Although the precise mechanisms of IT are not fully eluci-
dated, CP is a therapeutic strategy for brain damage improve-
ment in patients at high risk for ischemic brain injury.
Inﬂ ammation
Cerebral ischemia leads to immune reaction, with nonspeciﬁ c 
inﬂ ammatory cell inﬁ ltration, peripheral leukocytes migra-
tion to brain, and microglia activation 40. Moreover, ischemic 
neurons release inﬂ ammatory cytokines (IL-1 and TNF-α). 
Glia lead to the generation of adhesion molecules (selectins, 
integrins, intercellular adhesion) in cerebral vasculature, 
resulting in increased permeability of the blood-brain barrier 
(BBB) and culminating in edema formation 41,42.
Cytokine secretion and proteases, such as metalloprotei-
nases, causes further disruption of the extracellular matrix 
and BBB. Although IL-1 is responsible for cerebral ischemic 
injury, the functions of other cytokines such as IL-6 (a 
proinﬂ ammatory cytokine) and IL-10 (an anti-inﬂ ammatory 
cytokine) are less clear. TNF-α is not only responsible for 
ischemic brain inﬂ ammation 43, but plays a role in propagat-
ing brain injury 44,45.
Nimesulide, a cyclooxygenase-2 inhibitor, has been shown 
to attenuate lesion in the hippocampus CA1 region in a 
gerbil model when administered orally or intraperitoneally 
as a pre- or post-treatment of up to 24 hours 46. Additional 
experimental studies in animal models are needed to conﬁ rm 
these ﬁ ndings and frame them in a clinical paradigm.
Immunosuppressants, such as cyclosporine and acrolimus, 
are immunophilin and calcineurin inhibitors and potent apop-
tosis inducers. Administration of both agents for three days 
before ischemia provided seven days of neuroprotection in 
an animal model of global cerebral ischemia 47. These agents 
also attenuated the activity of calcineurin in CA1 and CA3 and 
dentate gyros of hippocampus within 24 hours after ischemic 
injury. Pretreatment with cyclosporin inhibits the dephospho-
rylation of proapoptotic BAD protein. Cyclosporin inability to 
cross the intact BBB is a signiﬁ cant therapeutic concern.
These agents require more rigorous testing for post-
ischemia treatment in different animal species and global 
models of cerebral ischemia 39.
Glycemia
A series of traumatic brain injury studies of animal models 48, 
focal cerebral ischemia 49, and global cerebral ischemia 50 
found that glycemic control is a critical factor in IT. Several 
mechanisms have been proposed for brain injury genesis, 
including marked release of excitatory amino acids (EAAs), 
reduced release of neuroinhibitory transmitters 51, massive 
deposition of neutrophils 52, and mitochondrial damage by 
cytochrome-c activation, caspase-3 and caspase-9 53. These 
studies led to clinical observations that a poor glycemic con-
trol increases brain damage in ischemic stroke 54,55. Glycemic 
control with insulin showed better neurologic outcomes 
in critically ill patients, as well as in patients undergoing 
cardiac surgery 55,56. Although insulin therapy has shown 
improvement in brain damage in animal models of global 
cerebral ischemia 57, further clinical trials of glycemic control 
management with insulin therapy are needed.
Temperature
Functional outcome and histopathology of animal model 
experimental studies of global and focal cerebral ischemia 
provided evidence for the importance of brain temperature 58. 
During a cerebral ischemic event, hyperthermia leads to 
incomplete normalization of phosphate metabolism, which re-
sults in microvascular injury and edema, leading to increased 
mortality 58. Spontaneous increases in body temperature have 
been reported after experimental focal and global ischemia 
and may be a consequence of brain damage 59.
Induced mild (34°C) to moderate (30°C) hypothermia 
reduces ischemic brain injury after experimental cardiac 
arrests 60. Neuroprotective mechanisms induced by hypother-
mia may be multifactorial and include biosynthesis pre- and 
post-synaptic processes, release and absorption of EAAs, 
decreased production of hydroxyl radical, membrane lipo-
protein protection, intracellular acidosis, and demand for 
oxygen by the injured brain 61.
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The neuroprotection induced by hypothermia can be 
divided into acute and delayed. Experts agree that the 
activation of cell signaling molecules, such as adenosine 
receptors, tyrosine kinase, and potassium channels, is 
important for the development of CP-induced ischemic or 
anesthetic events. Studies show that adenosine receptor 
activation may lead to the opening of ATP-sensitive potas-
sium channels, which induces the production of oxygen free 
radicals to activate the Ras/Raf pathway. This pathway is 
part of the kinase cascade and responsible for activating 
the Ras protein, a product of a proto-oncogene acting as a 
G protein (transmits signal through the exchange of GDP/
GTP) and is associated with plasma membrane. The Ras 
protein activates a kinase cascade and is responsible for 
successive phosphorylations, starting with Raf activation, 
responsible for the activation of other proteins, up to the 
last one (MAP), which will activate transcription factors 
that will act on gene transcription, resulting in increased 
expression of genes responsible for insulin production and 
other growth factors involved in CP 62-66.
Hypothermia also inhibits the high-mobility group HMG-
I(Y), an important nuclear transcription protein responsible 
for increased expression of NO synthetase, cyclooxygen-
ase-2, and cytokines that, in turn, are responsible for the 
development of post-ischemia brain lesions. However, it 
is unclear whether preconditioning hypothermia-induced 
inhibition of protein expression HMG-I (Y) plays a role in 
the development of acute, delayed or of both neuroprotec-
tive phases 67.
Nishio et al. 32 suggest that protein synthesis is required 
for developing preconditioning induced by hypothermia in 
the late neuroprotection phase.
Recent clinical trials have demonstrated better neurologi-
cal outcome and reduced mortality in patients undergoing 
mild or moderate therapeutic hypothermia 67. Future studies 
should incorporate other pharmacological neuroprotective 
strategies combined with hypothermia, in order to achieve 
better results.
Calcium channel antagonists
Ca2+ is the ﬁ nal common pathway in excitotoxic neuronal 
injury.
Nimodipine, a Ca2+ channel blocker, has been stud-
ied in experimental models of global cerebral ischemia. 
Subcutaneous administration of nimodipine failed to show 
any neurological, histological, or functional improvement 
in rat models of global cerebral ischemia 68,69. However, 
treatment with intravenous nimodipine in a rabbit model 
reduced EEG recovery time, attenuated the decrease of 
extracellular Ca2+ and decreased BBB disruption. In this 
study, blood pressure was maintained at 100 mm Hg after 
ischemic insult, which offset the hypotensive adverse ef-
fects of nimodipine.
A double-blind, prospective, randomized trial of ni-
modipine in patients who had ventricular ﬁ brillation outside 
hospitals failed to show any improvement in survival rate for 
one year; however, it did show some beneﬁ t in patients with 
resuscitation delayed for more than 10 minutes 70.
NMDA Receptor antagonists
Pre- and post-treatment with dextrorphan (NMDA receptor 
antagonist) improved histological damage in the hippocampus 
and cortex of ischemic model in rats and attenuated the 
loss of calcium-dependent protein kinase activity, such as 
calmodulin 71.
Although dizocilpine (another NMDA receptor antagonist) 
has shown signiﬁ cant histological neuroprotection in animal 
models of global cerebral ischemia 72, its use in clinical 
courses of ischemic insults produced signiﬁ cant adverse 
events (delirium, psychosis, hallucinations) 73.
GABA agonists
The premise of using gamma-Aminobutyric acid (GABA) or 
its agonists as neuroprotectors is based on their inhibitory 
properties in opening chloride channels 39. Pretreatment 
with GABA demontratedly attenuates histological injury and 
improves the nervous system’s behavior in a model of global 
cerebral ischemia in gerbils 74. The treatments after the insult 
failed to show any improvement in these parameters.
Clormetiazol, a GABA agonist with anticonvulsant, hyp-
notic, and sedative properties, showed no improvement in 
histological damage or neurobehavior in a murine model of 
global cerebral ischemia 75. Furthermore, local infusion of 
clormetiazol through microdialysis did not change the release 
of dopamine, serotonin or its induced-ischemia metabolitesin 
the ischemic stratum 75.
Intraperitoneal administration of G-hydroxybutyrate im-
proved histological and neurobehavioral injury in a murine 
model of global cerebral ischemia 76.
The use of tiagabine, a selective inhibitor of GABA uptake, 
resulted in no histological improvement in a gerbil model 
when given as a pretreatment 77.
Anticonvulsants
The basis for using anticonvulsants in ischemic neuroprotec-
tion is its ability to stabilize neurons by hyperpolarization 
of membrane potential by blocking voltage-dependent Na+ 
channel 39.
Treatment with phenytoin reduces K+ accumulation in 
cerebrospinal ﬂ uid of animals undergoing circulatory ar-
rest. Some studies of phenytoin therapy showed decreased 
cerebral edema, increased activity of Na+/K+ ATPase enzyme, 
decreased intracellular Na+ concentration, and reduced ac-
cumulation of lactate and free fatty acids 78.
The use of lamotrigine reduced the increase of extracel-
lular glutamate levels induced by ischemia, with histologic 
improvement in models of global cerebral ischemia (rats 
and gerbils) 79.
Erythromycin
Studies of erythromycin showed improvement in neurological 
function and increased neuronal survival after ischemia 80.
The neuroprotective effect of erythromycin in mice is 
associated with increased expression of anti-apoptotic gene 
bcl-2.
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Pretreatment with erythromycin 12 hours before the 
ischemic event improved postischemic neuronal survival in 
hippocampal areas (CA1 and CA3) and reduced functional 
deﬁ cit. Studies indicate that the neuroprotective effect of 
erythromycin lasts up to seven days.
This erythromycin effect suggests a clinical strategy 
of ischemic preconditioning, which could be beneﬁ cial to 
patients scheduled for surgical procedures associated with 
increased risk of perioperative cerebral ischemia (e.g., 
cardiovascular surgery or neurosurgery). Future studies are 
needed to determine the clinical role of this novel method 
of neuroprotection and clarify the molecular mechanisms 
involved.
Neuroprotection induced by anesthetics
Several studies in vitro 85 and in vivo in the last 20 years 
have reported neuroprotection induced by anesthesia 86,87 
in different species 88-90 and in hemispheric 92 and global 93,95 
models of focal ischemia 91,92.
Most anesthetic agents have neuroprotective properties, 
although neuroprotection is not correlated with anesthetic 
efﬁ cacy. The use of anesthetics to induce neuroprotection 
depends not only on its potency, but also on the administra-
tion method, side effects, and patient tolerability.
A major concern is the apparent lack of long-term neuro-
protective effects of some anesthetic agents 81.82.
GABAergic agents
The main receptor of volatile anesthetics is believed to be 
GABA 83.
The inhibitory neurotransmission via GABA receptor 
modulation contributes to anesthesia. Therefore, it is not 
surprising that reduced neuronal excitability induced by 
GABAergic agents may also reduce excitotoxicity.
Sanders et al. 7 reported neuroprotection induced by 
GABAergic anesthetic agents using examples of volatile and 
intravenous agents. This study considered the suppression 
of cerebral metabolic rate (CMR) as a possible mechanism 
of neuroprotection induced by anesthetics.
Volatile anesthetics
The neuroprotective potential of volatile anesthetics, 
particularly isoﬂ urane, was highlighted by some authors 84. 
Isoﬂ urane has shown to be an anesthetic agent with sig-
niﬁ cant neuroprotective effects, with the ability to reduce 
excitotoxicity.
Isoﬂ urane proved to be a superior neuroprotective agent 
to a combined regimen of nitrous oxide and fentanyl in mice 
assessed three days after bilateral carotid artery occlusion 
in cognitive and histological function tests 94. Additionally, 
in a model of traumatic brain injury in rats, isoﬂ urane pro-
vided better neuroprotection than fentanyl when both were 
administered in combination with nitrous oxide 28.
Some studies suggest that isoﬂ urane reduces the cerebral 
metabolic rate and, therefore, inhibits excitotoxicity. This 
effect appears to be independent of peri-ischemic cerebral 
blood ﬂ ow, despite isoﬂ urane vasodilating properties 95. The 
neuroprotective effect of anesthetics is also independent of 
intracranial pressure.
Isoﬂ urane reduced neurological deﬁ cit in about 20% of 
the sample in a canine model of cardiac arrest, compared 
to control group 88. Administration of isoﬂ urane for 5 hours 
post-injury showed reduced excitotoxicity mediated by 
α-amino-d-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) 
injury, a subtype of glutamate receptors 86. In contrast with 
pentobarbital, which was effective only at a cerebral sup-
pression dose, isoﬂ urane was effective in anesthetic doses.
Another volatile anesthetic, desﬂ urane, also showed neu-
roprotective properties equivalent to those of isoﬂ urane in 
an animal model of incomplete cerebral ischemia, and both 
agents proved to be superior to fentanyl and nitrous oxide 
based anesthesia 96.
In vitro studies showed that the effect of reducing cer-
ebral metabolic rate is not sufﬁ cient to explain the neuro-
protective effects of volatile anesthetics.
Sanders et al. 7 used gabazine, a GABA receptor antago-
nist, to elucidate whether this effect could be attributed to 
these receptors. Gabazine showed a similar neuroprotec-
tive mechanism. Likewise, Bickler et al. 97 showed that the 
neuroprotective effect of isoﬂ urane is dependent on GABA 
receptors with the use of bicuculline, another GABA recep-
tor antagonist.
Volatile anesthetics may also protect against glutamate 
excitotoxicity and promote its uptake. This action cannot 
be obtained with pentobarbital, an intravenous anesthetic 
agent that also exerts neuroprotective effect 98. Interestingly, 
isoﬂ urane and thiopental share the ability to prevent de-
crease in phosphorylation of focal adhesion kinase (FAK 
pp125), induced by oxygen-glucose deprivation in vitro. The 
pp125 FAK interacts with cell survival cascades mediated by 
MAPK (ERK1 and 2) and AKT. However, despite interaction 
with these pathways, isoﬂ urane showed no anti-apoptotic 
properties 82.
Intravenous anesthetics
Barbiturates were introduced as effective neuroprotective 
agents and considered the “gold standard”, compared to 
other neuroprotective agents. However, more recent data 
refute this status. In the early 1970s, Yatsu et al. 99 reported 
that metohexital had neuroprotective activity. This study was 
followed by a series of studies reporting the neuroprotec-
tive efﬁ cacy of this class of agents. However, initial studies 
showed no temperature control and this led to overestimation 
of these drugs’ effects.
In more controlled settings, barbiturates provide some 
protection, but not in terms of an impressive suppression of 
cerebral metabolic rate.
There was no difference in infarct volume after transient 
focal cerebral ischemia when comparing the use of low and 
high doses of thiopental, although these doses have clear 
differences in the ability to produce EEG suppression and, 
therefore, in brain metabolism 100. Pentobarbital showed 25% 
reduction of infarct volume in a model of middle cerebral 
artery occlusion in rats 25% 101.
Direct comparison between metohexital and isoﬂ urane 
shows that isoﬂ urane MAC 2 was more potent against severe 
ischemia in rats than metohexital (0.1 mg.kg-1.min-1). The 
depression effect of cerebral metabolic rate was similar 
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for both drugs; however, unlike isoﬂ urane, metohexital 
anesthetic doses have no neuroprotective effects during 
complete ischemia 102.
Barbiturates have neuroprotective efﬁ cacy against less 
severe insults. Milde et al. 103 found no difference between 
thiopental and isoﬂ urane during temporary focal ischemia. 
However, a previous study had shown that in baboons, thio-
pental was a neuroprotective agent superior to isoﬂ urane, 
although this study has shown the major hemodynamic dif-
ference bias between groups 104.
Zausinger et al. 105 recently compared in a model of 
transient focal ischemia in rats two combination therapies: 
the common treatment regimen (CTR) with nimodipine, 
mannitol, dexamethasone, and methohexital and the alter-
nate treatment regimen (ATR) with magnesium, tirilazad, 
and mild hypothermia. Monotherapy with metohexital was 
effective and dexamethasone, mannitol, and nimodipine, 
alone or in combination, were not effective. CTR was not 
more effective than metohexital as a therapy, although it 
signiﬁ cantly reduced infarct volume. ATR was very effective 
and reduced infarction in 73% of samples without resulting in 
neurological deﬁ cit. This effect was signiﬁ cantly higher than 
CTR. Furthermore, hypothermia has shown neuroprotective 
effects in clinical trials 106, and pharmacological agents are 
likely to be judged as adjuvant therapy in this setting. In this 
study, barbiturates showed no additional protective beneﬁ t 
over hypothermia alone 107.
Clinical trials investigating the neuroprotective ef-
fects of barbiturates yielded contradictory results. Ward 
et al. 108 used barbiturates in 53 patients with traumatic 
skull-brain injury, and neurological outcome was similar 
to the control group.
In contrast to hypothermia, thiopental is an ineffective 
neuroprotective agent to follow cardiac arrest 109. Thiopental 
administered at doses to produce EEG suppression 110 was 
ineffective in preventing strokes in patients with coronary 
artery bypass grafting. Thiopental was also associated with 
prolonged extubation and higher pressure requirements. 
In contrast, Nussmeier et al. 111 showed that thiopental 
exerted neuroprotection during cardiac surgery with cardi-
opulmonary bypass at normothermia 111 and reduced stroke 
incidence. Numerous differences in study methodologies 
could explain this discrepancy, which included air embolism, 
normothermia, hypothermia, and duration of therapy with 
barbiturates. However, this study of 182 patients is the 
only clinical trial suggesting the neuroprotective effect of 
barbiturates.
Thus, barbiturates may provide modest neuroprotection, 
but are not superior to other anesthetics, besides being po-
tentially less additives when combined with hypothermia.
Propofol
Propofol has proved itself to be neuroprotective in vivo in 
models of focal 112 and Global 113 cerebral ischemia. This 
anesthetic-induced neuroprotection is most likely due to its 
antioxidant effects, the activation of its phenolic hydroxyl 
group. However, the hypothesis of CP induced by its effect 
on glutamate uptake, dopamine release or GABA receptor 
activation is not dismissed. The use of propofol also resulted 
in up-regulation of Bcl-2 and mdm-2 expression and down-
regulation of Bax expression after brain ischemia in rats, 
which show an anti-apoptotic action of this drug. However, 
this action has not been histologically documented 114.
Clinically, cerebral suppression doses of propofol were 
not superior to sufentanil after open-heart surgery, assessed 
by the incidence of cognitive dysfunction, depression, or 
anxiety 115.
Alfa-2 agonists
The use of in vivo α2-agonists agents reduced neurologi-
cal blockade after ganglionic injury with hexamethonium 
in a model of incomplete cerebral ischemia in rats 116. This 
neuroprotective effect is partially reversed by intravenous 
administration of norepinephrine and epinephrine.
Subsequently, it became evident that neurological out-
come is improved in rats receiving clonidine after incomplete 
cerebral ischemia by decreasing high catecholamine levels 
in blood 117.
Administration of dexmedetomidine pre-ischemia sig-
niﬁ cantly reduced the levels of plasma catecholamines and 
decreased neurological comorbidities at functional and patho-
physiological parameters 118. Furthermore, Maier et al. 119 re-
ported neuroprotective effects even when dexmedetomidine 
was administered in a model of transient focal ischemia in 
rabbits (plasma concentration 4 ng.mL-1) 119.
The clinical use of α2-agonists as neuroprotective agents 
has not been determined.
NMDA antagonists 
Ketamine, nitrous oxide, and xenon have anesthetic action 
by antagonizing NMDA glutamate receptors. The key-role of 
NMDA receptor in neurotoxicity led to numerous investiga-
tions of these anesthetics’ potential to induce neuronal 
survival after injury.
The use of this class of agents has been hampered by 
psychomimetic effects associated with neuronal vacuola-
tion in the posterior cingulate and retrosplenial cortex 120. 
These psychomimetic side effects may worsen during 
ischemia 121, adding concern regarding the use of these 
agents as neuroprotectors.
While in vitro ketamine shows neuroprotective effects 122, 
in vivo results were not consistent. Proescholdt et al. 123 re-
ported that S-(+) ketamine showed neuroprotective potency 
over R-(+) ketamine and racemic mixture. This difference 
in neuroprotective efﬁ cacy is consistent with the larger 
hypnotic and analgesic effects of S-(+) ketamine.
Very high doses of ketamine are necessary to achieve its 
ischemic protection ability 124. However, high doses increase 
the risk of adverse effects, such as seizures and psycho-
mimetic disorders. Nevertheless, high-dose ketamine has 
neuroprotective effects on cortical ischemia in vivo 123-124.
Ketamine was similar to remifentanil in a randomized 
controlled trial comparing the neuroprotective efﬁ cacy 
in open-heart surgery in combination with propofol 125. 
The vasodilatory effect of ketamine may increase emboli 
movement, an event that could reduce its neuroprotective 
effect.
Arrowsmith et al. 126 reported a neuroprotective effect of 
this anesthetic during cardiopulmonary bypass (CPB), with 
perioperative application of the NMDA antagonist rema-
cemide, although it was only similar to a secondary endpoint. 
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One hundred and seventy-one patients were tested with a 
neuropsychological battery pre- and post-operatively. There 
was no signiﬁ cant difference between groups on individual 
tests; however, the overall change in the postoperative period 
was better in the remacemide group.
Nitrous Oxide
Nitrous oxide has the neuroprotective and neurotoxic charac-
teristics of a NMDA antagonist 127. However, numerous studies 
have identiﬁ ed that the neuroprotection induced by nitrous ox-
ide combined with an opioid is less potent than that induced by 
an inhaled anesthetics. Recently, experiments demonstrated 
that nitrous oxide has no neuroprotective effects in rats 128.
Xenon
Xenon’s ability to act as a neuroprotective agent was dem-
onstrated in several neuronal injury paradigms.
Xenon in vitro reduced cortical injury in rats, induced by 
NMDA, glutamate, or oxygen deprivation 129. Another in vitro 
study showed that 50% xenon might reduce neuronal cell 
death induced by hypoxia 130, an effect that could be partly 
antagonized by calcium.
In clinical practice, xenon administration is usually given 
in combination with other anesthetics. Recently, it was dem-
onstrated that co-administration of isoﬂ urane synergistically 
increases xenon neuroprotection in vitro. This can be of great 
clinical importance, as xenon on its own is not sufﬁ ciently 
potent to induce anesthesia because of its higher MAP value 
(63-71%), aside from being extremely expensive. Additionally, 
the possibility of synergic multimodal therapies administra-
tion is likely to provide long-term neuroprotection.
Xenon attenuated neuronal damage induced by N-methyl-
D-aspartate (NMDA) administration in rats 129. Sanders et al. 130 
reported its neuroprotective effect in a model of focal 
ischemia with 70% xenon administration during ischemia 
induced by cerebral artery occlusion in rats and showed 
a signiﬁ cant reduction in total infarct size, cortical and 
subcortical, compared to nitrous oxide 130. Xenon provided 
superior neurocognitive protection than nitrous oxide, as 
shown by two of the three cognitive tests performed 24 
hours after ischemia.
In a study evaluating the effect of xenon on a model of 
cardiopulmonary bypass (CPB) 131, we observed an attenuation 
of cognitive dysfunction caused by CPB up to 12 days after 
injury, an effect that was greater than that observed with 
the prototypical NMDA antagonist, MK801.
Some neurological injuries, such as perinatal brain injury, 
may not be predicted and, therefore, a neuroprotective agent 
cannot be administered before its occurrence. Therefore, 
research on the effectiveness of an agent with post-injury 
administration is important for clinical application in these 
scenarios. In a model of transient global ischemia, which 
occluded the middle cerebral artery in adult rats during 90 
minutes, 50% xenon administered over 3 hours, starting 15 
minutes after the insult, signiﬁ cantly reduced the neuronal 
damage in the striatum cortex. However, this study showed 
that 70% xenon was ineffective 132. Theoretically, post-
ischemic treatment with xenon may be used in neurological 
conditions, such as stroke.
Xenon MAP is estimated at 63% to 71%; thus, the concen-
trations needed for neuroprotection are signiﬁ cantly sub-
anesthetic. In contrast with other drugs requiring  anesthetic 
or supra-anesthetic doses to act as neuroprotective agents, 
xenon can be effective in clinically acceptable concentra-
tions, when anesthesia is not required or may be detrimental 
(e.g.,  patients with cardiovascular impairment).
Unlike other NMDA antagonist receptors, xenon does not 
induce damage to the posterior cingulate and retrosplenial 
cortex 133. Nagata et al. 134 demonstrated that xenon might 
improve the neurotoxic effect of other NMDA antagonists.
Recent in vitro investigations have suggested that xenon 
acts not only on NMDA receptors, but also activates the two 
pore domain of potassium channel TREK-1. TREK-1 channels 
are activated by intracellular acidosis, reduce neuronal ex-
citability, and contribute to neuroprotection 135.
Conclusion
The brain has the ability to protect itself against ischemia 
when stimulated by appropriate factors. The elucidation 
of this mechanism resulted in the possibility of applying 
CP-inducing substances, such as some anesthetics, in medi-
cal practice. In operations requiring periods of ischemia or 
cerebral hypoperfusion, the anesthesiologist may intervene 
with drug administration and non-pharmacological meas-
ures, such as hypothermia, aiming at inducing tolerance to 
ischemic lesions.
Thus, deﬁ ning the best strategy for nervous system pro-
tection is of paramount importance in reducing intraopera-
tive neuropsychological impairment.
Combined inhaled anesthetics, such as isoﬂ urane and 
xenon, is a good pharmacological alternative for intraop-
erative CP consolidation and, perhaps, against nonsurgical 
damages. Future studies may elucidate the most effective 
drug combination that could contribute to a better manage-
ment of IT.
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